EMICIZUMAB-KXWH: 9,283 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
9,283
Total FAERS Reports
261 (2.8%)
Deaths Reported
1,241
Hospitalizations
9,283
As Primary/Secondary Suspect
61
Life-Threatening
31
Disabilities
First Report: 20080901 · Latest Report: 20250923
What Are the Most Common EMICIZUMAB-KXWH Side Effects?
#1 Most Reported
Haemorrhage
3,612 reports (38.9%)
#2 Most Reported
No adverse event
654 reports (7.0%)
#3 Most Reported
Off label use
542 reports (5.8%)
All EMICIZUMAB-KXWH Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Haemorrhage | 3,612 | 38.9% | 15 | 403 |
| No adverse event | 654 | 7.1% | 0 | 0 |
| Off label use | 542 | 5.8% | 22 | 54 |
| Haemarthrosis | 487 | 5.3% | 1 | 71 |
| Fall | 484 | 5.2% | 9 | 100 |
| Arthralgia | 385 | 4.2% | 1 | 31 |
| Contusion | 321 | 3.5% | 1 | 22 |
| Epistaxis | 313 | 3.4% | 0 | 26 |
| Pain | 260 | 2.8% | 0 | 26 |
| Head injury | 248 | 2.7% | 4 | 42 |
| Muscle haemorrhage | 222 | 2.4% | 0 | 35 |
| Mouth haemorrhage | 177 | 1.9% | 2 | 30 |
| Weight increased | 174 | 1.9% | 1 | 18 |
| Joint injury | 163 | 1.8% | 0 | 18 |
| Injury | 158 | 1.7% | 3 | 32 |
| Limb injury | 154 | 1.7% | 0 | 19 |
| Headache | 131 | 1.4% | 0 | 11 |
| Injection site pain | 131 | 1.4% | 0 | 2 |
| Joint swelling | 125 | 1.4% | 0 | 16 |
| Drug ineffective | 122 | 1.3% | 1 | 8 |
Who Reports EMICIZUMAB-KXWH Side Effects? Age & Gender Data
Gender: 3.6% female, 96.4% male. Average age: 30.0 years. Most reports from: US. View detailed demographics →
Is EMICIZUMAB-KXWH Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2008 | 1 | 0 | 0 |
| 2017 | 4 | 2 | 2 |
| 2018 | 75 | 1 | 21 |
| 2019 | 189 | 5 | 63 |
| 2020 | 199 | 20 | 58 |
| 2021 | 300 | 15 | 65 |
| 2022 | 389 | 19 | 87 |
| 2023 | 1,006 | 25 | 153 |
| 2024 | 1,061 | 26 | 165 |
| 2025 | 543 | 20 | 108 |
What Is EMICIZUMAB-KXWH Used For?
| Indication | Reports |
|---|---|
| Factor viii deficiency | 6,532 |
| Product used for unknown indication | 1,097 |
| Haemophilia a without inhibitors | 589 |
| Haemophilia | 402 |
| Acquired haemophilia | 267 |
| Haemophilia a with anti factor viii | 128 |
| Factor vii deficiency | 94 |
| Von willebrand's disease | 90 |
| Prophylaxis | 55 |
| Haemorrhage prophylaxis | 17 |
EMICIZUMAB-KXWH vs Alternatives: Which Is Safer?
EMICIZUMAB-KXWH vs EMPAGLIFLOZIN
EMICIZUMAB-KXWH vs EMPAGLIFLOZIN\LINAGLIPTIN
EMICIZUMAB-KXWH vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN
EMICIZUMAB-KXWH vs EMPAGLIFLOZIN\METFORMIN
EMICIZUMAB-KXWH vs EMSAM
EMICIZUMAB-KXWH vs EMTRICITABINE
EMICIZUMAB-KXWH vs EMTRICITABINE\RILPIVIRINE\TENOFOVIR ALAFENAMIDE
EMICIZUMAB-KXWH vs EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL
EMICIZUMAB-KXWH vs EMTRICITABINE\TENOFOVIR
EMICIZUMAB-KXWH vs EMTRICITABINE\TENOFOVIR ALAFENAMIDE
Official FDA Label for EMICIZUMAB-KXWH
Official prescribing information from the FDA-approved drug label.